Can I Take Glycine with Ipamorelin?

What Is Ipamorelin and How Does It Work?

Ipamorelin acetate is a synthetic pentapeptide growth-hormone secretagogue. It binds the ghrelin receptor (GHSR-1a) in the pituitary and hypothalamus, triggering a selective, pulsatile release of growth hormone without the cortisol or prolactin spikes associated with older secretagogues like GHRP-6. Raun et al. First characterized this selectivity in 1998, demonstrating that ipamorelin produces GH pulses comparable in amplitude to GHRP-6 while keeping ACTH and cortisol responses near baseline in animal models [1].

The GH Pulse Profile

After a 200 mcg subcutaneous injection, GH concentrations typically peak within 30 to 60 minutes and return toward baseline within 2 to 3 hours. This narrow pulse window matters when you are co-administering any compound that also modulates GH secretion, including glycine.

Regulatory Status

In the United States, ipamorelin is compounded under section 503A of the Federal Food, Drug, and Cosmetic Act and is not FDA-approved as a finished drug product. The FDA's guidance on 503A compounding requires individual patient prescriptions from licensed practitioners [2]. Patients should confirm their compounding pharmacy holds the appropriate state licensure.

What Is Glycine and Why Do People Take It?

Glycine is the simplest amino acid and a conditional essential nutrient. The average adult synthesizes roughly 3 g of glycine per day endogenously, yet dietary and metabolic demands can reach 10 g per day, creating a shortfall that supplements can address. A 2009 analysis in Glycine metabolism in animals and humans estimated the biosynthetic deficit at approximately 10 g/day under physiological stress [3].

Sleep Quality

A 2012 placebo-controlled crossover trial (N=11) published in Sleep and Biological Rhythms found that 3 g of glycine taken 1 hour before bed reduced self-reported fatigue and improved sleep-onset latency. Polysomnography showed shorter time to slow-wave sleep versus placebo. The full text is indexed on PubMed [4]. Because ipamorelin is most commonly injected near bedtime to coincide with the nocturnal GH surge, both compounds end up in the same administration window by default.

Collagen and Connective Tissue

Glycine constitutes approximately 33% of all collagen residues, making it the most abundant amino acid in the extracellular matrix. A 2019 randomized trial (N=102) in the British Journal of Nutrition found that 15 g of collagen hydrolysate (delivering roughly 3 g of glycine) daily for 12 weeks increased collagen synthesis markers in athletes with knee pain [5]. Patients combining ipamorelin with glycine for body-composition or connective-tissue goals have a plausible synergistic rationale, though no dedicated trial has tested the combination.

Glycemic Considerations

Glycine also has an insulin-secretagogue effect at pharmacological doses. A study in Diabetes Care showed that oral glycine 5 g three times daily for 3 months modestly improved insulin sensitivity in obese patients with type 2 diabetes compared to placebo [6]. This matters because GH itself is counter-regulatory to insulin, and ipamorelin raises GH concentrations acutely.

Is the Ipamorelin-Glycine Interaction Pharmacokinetic or Pharmacodynamic?

The interaction is pharmacodynamic, not pharmacokinetic. This is a meaningful distinction.

Why There Is No Pharmacokinetic Interaction

Ipamorelin is a peptide administered subcutaneously. It does not undergo significant hepatic first-pass metabolism and is not a substrate, inducer, or inhibitor of cytochrome P450 enzymes. Glycine is an amino acid absorbed via sodium-coupled transporters in the small intestine and processed largely in the liver and kidney. The two compounds use entirely different absorption routes, metabolic pathways, and elimination mechanisms. No published ADME data suggest any competition for plasma proteins, transporters, or enzymatic degradation between ipamorelin and glycine [1,3].

Where Pharmacodynamic Overlap Occurs

Three areas of overlap are worth understanding:

GH axis. Both compounds can stimulate GH secretion, though through different mechanisms. Ipamorelin acts directly on GHSR-1a. Glycine, at higher doses, may stimulate GH release via N-methyl-D-aspartate (NMDA) receptor modulation in the hypothalamus. A 1990 study in the Journal of Clinical Endocrinology and Metabolism demonstrated that oral glycine 6.75 g produced a statistically significant rise in plasma GH in healthy adults (peak GH 3.6 ± 0.6 ng/mL vs. 0.9 ± 0.2 ng/mL on placebo, P<0.05) [7]. If both compounds are administered at the same time, the GH pulse could be additive. Whether a larger GH pulse is desirable or problematic depends on individual goals and baseline IGF-1 levels.

Sleep architecture. Both ipamorelin (through the nocturnal GH pulse) and glycine (through NMDA receptor and glycine-receptor agonism in the hypothalamus) may improve slow-wave sleep. Co-administration near bedtime likely amplifies this effect, which most patients find beneficial rather than harmful.

Insulin sensitivity. GH acutely reduces peripheral glucose uptake. Glycine, at the doses used in metabolic research, may modestly improve insulin sensitivity. These opposing effects partially offset each other, but patients with pre-existing insulin resistance warrant closer glucose monitoring [6,7].

Optimal Timing: How to Separate the Doses

The practical goal is to capture ipamorelin's GH pulse cleanly before introducing glycine's own modest GH signal, or to allow glycine's sleep-onset effect to develop without blunting the ipamorelin-induced GH peak by competing for neuroendocrine resources.

A clinically reasonable approach, based on the pharmacokinetic profiles described above:

1. Inject ipamorelin 30 to 60 minutes before bed, on an empty stomach (food, especially carbohydrates, blunts the GH response).
2. Take glycine 3 g orally roughly 30 to 60 minutes after the ipamorelin injection, or alternatively take it 60 minutes before the injection if you prefer the pre-sleep glycine ritual first.
3. Avoid simultaneous dosing only if you are monitoring IGF-1 tightly and want the cleanest possible attribution of GH response to ipamorelin.

The 2012 glycine sleep trial used a 3 g dose 1 hour before bed [4]. Ipamorelin GH peaks at 30 to 60 minutes post-injection [1]. A 30-minute gap between injection and glycine ingestion keeps the two GH-stimulatory signals offset by at least one half-peak interval.

Monitoring Recommendations

IGF-1 and Growth Hormone

Patients on ipamorelin typically check serum IGF-1 at baseline and every 3 months. Adding glycine does not change this interval, but if IGF-1 rises above the age-adjusted upper reference range (generally above 300 ng/mL in adults under 40), reviewing total GH stimulation, including any supplemental glycine dose, is appropriate. The Endocrine Society's 2019 Clinical Practice Guideline on Growth Hormone Deficiency recommends titrating GH therapy to maintain IGF-1 in the mid-normal range for age and sex [8].

Fasting Glucose and HbA1c

Because GH is counter-regulatory to insulin, ipamorelin can raise fasting glucose modestly in some patients. Glycine at 3 g before bed is unlikely to meaningfully affect overnight glucose given the doses used in sleep research, but the larger doses used in metabolic studies (5 g three times daily) do influence glucose metabolism [6]. Check fasting glucose and HbA1c at baseline and every 3 months for the first year.

Blood Pressure and Kidney Function

Glycine at doses above 10 g/day has been studied as a renoprotective agent. A trial published in Nephrology Dialysis Transplantation found no adverse renal effects at 3.6 g/day over 12 weeks [9]. Standard doses of 3 g/day carry no identified nephrotoxic risk, and ipamorelin at research doses (100 to 300 mcg/day) has not been associated with renal adverse events in published preclinical data [1].

What the Evidence Does (and Does Not) Support

Published data on the specific combination of ipamorelin plus glycine in humans does not exist as of early 2025. Conclusions about the interaction derive from:

• Ipamorelin's mechanism and safety profile in animal and human-pilot studies [1].
• Glycine's GH-stimulating effect at supraphysiological oral doses [7].
• Glycine's sleep and metabolic data from small-to-moderate RCTs [4,5,6].
• General pharmacokinetic principles confirming no shared metabolic pathway.

The absence of a dedicated combination trial means that claims about synergistic anabolic or recovery effects remain speculative. Patients should set expectations accordingly and document their own response through objective biomarkers rather than subjective perception alone.

A 2022 review in Nutrients summarized the current evidence on glycine supplementation across multiple outcomes, including sleep, metabolic health, and inflammation, and noted that most benefits appear at doses of 3 to 5 g/day with a favorable safety profile up to at least 90 days of continuous use [10].

Special Populations and Contraindications

Patients with Diabetes or Prediabetes

Ipamorelin-associated GH pulses can transiently raise blood glucose. The American Diabetes Association's 2024 Standards of Care recommend that any intervention with potential glucose-elevating effects be monitored with HbA1c every 3 months in patients with existing diabetes [11]. Glycine may partially offset this rise at the doses used in the Housley et al. Trial [6], but the net effect in any individual patient is unpredictable without glucose monitoring.

Patients Taking GHRH Analogs (e.g., Sermorelin, CJC-1295)

Combining ipamorelin with a GHRH analog is a common clinical practice because the two act synergistically at different receptor sites. Adding glycine to that stack introduces a third GH signal. Patients on a GHRH/GHRP combination should be especially diligent about monitoring IGF-1 [8].

Pregnancy and Lactation

Neither ipamorelin nor high-dose glycine supplementation has been adequately studied in pregnancy. The FDA's general guidance on compounded drugs in pregnancy does not specifically address ipamorelin [2]. Patients who are pregnant or breastfeeding should not use ipamorelin.

Age Under 18

Growth-plate physiology in skeletally immature patients makes any GH secretagogue potentially risky. Glycine supplementation alone is not contraindicated in adolescents at dietary doses, but co-administration with ipamorelin in patients under 18 is not supported by any published evidence [1].

Practical Protocol Summary

Starting a glycine supplement while already using ipamorelin does not require stopping either compound. The following approach reflects current pharmacodynamic understanding:

• Confirm your ipamorelin prescription is from a 503A-compliant pharmacy before adding any supplement stack.
• Start glycine at 3 g, taken 30 to 60 minutes after your ipamorelin injection on evenings when you dose ipamorelin.
• Check fasting glucose after 2 weeks if you have any history of insulin resistance.
• Recheck IGF-1 at your next scheduled lab draw, typically 6 to 12 weeks after starting the combination.
• If IGF-1 exceeds the upper age-adjusted reference range, discuss dose reduction with your prescriber before attributing the rise solely to ipamorelin.

Glycine at 3 g/day is inexpensive, broadly available, and well-tolerated in short- and medium-term RCTs. The principal reason to be thoughtful about the combination is not toxicity but rather clean biomarker interpretation: when two GH-stimulatory agents are co-administered, attributing changes in IGF-1 or body composition to either one individually becomes harder.

Frequently Asked Questions